Reliability and validity of the CMT neuropathy score as a measure of disability.
about
A compound heterozygous mutation in HADHB gene causes an axonal Charcot-Marie-tooth diseaseAn exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AAscorbic acid for the treatment of Charcot-Marie-Tooth diseaseTreatment for Charcot-Marie-Tooth diseaseTreatment for Charcot-Marie-Tooth diseaseManagement of Charcot-Marie-Tooth disease: improving long-term care with a multidisciplinary approachSmall nerve fiber involvement in CMT1A.Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic AreaPsychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis.Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.A new locus for X-linked dominant Charcot-Marie-Tooth disease (CMTX6) is caused by mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene.Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trialNEFL N98S mutation: another cause of dominant intermediate Charcot-Marie-Tooth disease with heterogeneous early-onset phenotype.Two novel missense mutations in the myelin protein zero gene causes Charcot-Marie-Tooth type 2 and Déjérine-Sottas syndrome.Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A.A patient with neurofibromatosis type 1 and Charcot-Marie-Tooth disease type 1B.Dynamic transcriptional events in distal sural nerve revealed by transcriptome analysis.Recessive C10orf2 mutations in a family with infantile-onset spinocerebellar ataxia, sensorimotor polyneuropathy, and myopathyThe mutational spectrum in a cohort of Charcot-Marie-Tooth disease type 2 among the Han Chinese in TaiwanPostural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjectsProximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseasesNovel Compound Heterozygous Nonsense PRX Mutations in a Korean Dejerine-Sottas Neuropathy Family.MFN2 mutations cause severe phenotypes in most patients with CMT2A.Reliability of instrumented movement analysis as outcome measure in Charcot-Marie-Tooth disease: results from a multitask locomotor protocol.Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based surveySleep pattern in Charcot-Marie-Tooth disease type 2: report of family case series.Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.Association between brain volumes and HAND in cART-naïve HIV+ individuals from Thailand.A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy.A novel AARS mutation in a family with dominant myeloneuropathy.Natural history and biomarkers in hereditary sensory neuropathy type 1CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.A Mutation in PMP2 Causes Dominant Demyelinating Charcot-Marie-Tooth NeuropathyThe influence of somatosensory and muscular deficits on postural stabilization: Insights from an instrumented analysis of subjects affected by different types of Charcot-Marie-Tooth diseaseComparison between clinical disabilities and electrophysiological values in Charcot-Marie-Tooth 1A patients with PMP22 duplication.Intermediate Charcot-Marie-Tooth disease due to a novel Trp101Stop myelin protein zero mutation associated with debilitating neuropathic pain.Charcot-Marie-Tooth disease type 1A duplication with severe paresis of the proximal lower limb muscles: a long-term follow-up study.Charcot-Marie-Tooth disease: New insights from skin biopsyRapid progression of late onset axonal Charcot-Marie-Tooth disease associated with a novel MPZ mutation in the extracellular domain.
P2860
Q21261479-57B68848-3B69-4963-9B4F-AF10ADA03206Q22000603-B41EC253-CACC-4B9E-9438-B5014CFCA3CDQ24187132-6B79B725-5D56-49C7-A5E6-49F73E945E5EQ24242777-5691EF63-E09D-44CD-B437-FACB291766C0Q24244335-348F4CBF-077B-42AC-83EE-99770FCA186DQ26768401-FC72337D-F4DC-4340-84A2-187312528F1DQ27312053-4649788F-8060-4541-9554-87E2FA9B3B88Q29248271-7F95D44D-AD69-4426-B262-5F72CDA08EBDQ30301300-CCE37AC1-6912-4D5F-AA5B-2FB29408D77AQ30513760-723009FB-B88D-47AD-9760-196F755FA23EQ30537559-74170BE6-AB99-41E3-BDA4-17673CB8CEBBQ30543772-D5BAF3E3-9D7B-4620-96F0-669CAE24EE6FQ30883545-FF8FC722-F3C0-4FD7-8873-BCDCE5F67F3EQ31030793-1A220806-EC4A-44DA-9A4A-CB9B9673EF1EQ33552824-18E90C35-6D31-45C4-AB08-234D952EF8B1Q33567193-012B6E74-3964-41A4-893C-3B3551AF03ACQ33762006-E5088C1F-97B4-4B33-8B1C-55DB5A6F0E57Q33787353-A5929696-F1CF-429E-A277-9DE4BF2CF5F5Q33917481-19202132-D62C-4DDC-89FD-D7E1354D3968Q34113736-EF95B9C5-0333-4DED-84F3-35632C765B04Q34266756-D0170BC1-8E9D-4EE9-83AB-4A63973A13ACQ34465428-B92E0FD9-3BF5-4F30-8260-AF51872DDDF5Q34996566-1095C60E-B4FC-44A0-8039-80AF8BA4AC01Q34999364-51B6FD62-8921-422B-8F31-EB34F844B56BQ35039651-8B1C1E2E-13F9-4867-9F46-8EECAB41EA82Q35083966-1925B8A7-F75B-4420-95BD-853E32E5808BQ35138152-E770211B-A2B2-439F-9980-9505A0D2BABBQ35159258-EE86BA4C-5D42-42B5-803D-E94F26D8F011Q35220349-5BD64B28-6C8B-455E-9C42-E2996AAB5DA6Q35629933-848E3059-25EF-418F-AABB-A64650B81306Q35639969-471D3F5F-3C8B-43D7-98F0-962ADCDD6735Q35795032-36A76ADD-D248-4C3B-9728-1F26695517A7Q35891892-02646FD6-EDED-435A-87CF-B5E71331C444Q35909672-5BD85CE9-9381-4CEF-BD0A-9256E3E0EC34Q36007383-47BAE587-8DD6-45C3-BC59-D7B21A1E8DD6Q36081783-3D5C39C6-26C7-4716-9AFB-2506EE88F853Q36103150-BC92FDD2-AF34-4D6A-993D-B771804FD251Q36142401-9A3310E2-749D-4439-B3FA-B1835939B434Q36166978-A7654FBE-D947-4120-B736-56EDF76C2563Q36226776-6787370E-DFB9-4085-A6A9-EC9DC8D178BB
P2860
Reliability and validity of the CMT neuropathy score as a measure of disability.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Reliability and validity of the CMT neuropathy score as a measure of disability.
@en
Reliability and validity of the CMT neuropathy score as a measure of disability.
@nl
type
label
Reliability and validity of the CMT neuropathy score as a measure of disability.
@en
Reliability and validity of the CMT neuropathy score as a measure of disability.
@nl
prefLabel
Reliability and validity of the CMT neuropathy score as a measure of disability.
@en
Reliability and validity of the CMT neuropathy score as a measure of disability.
@nl
P2093
P1433
P1476
Reliability and validity of the CMT neuropathy score as a measure of disability
@en
P2093
Krajewski K
P304
P356
10.1212/01.WNL.0000156517.00615.A3
P407
P50
P577
2005-04-01T00:00:00Z